Iterum <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Q1 2025 Financial Results with Non-GAAP Net Loss Adjustments; Prepares for ORLYNVAHTM Launch by Q4 2025
Iterum Therapeutics plc, a company focused on delivering next-generation oral and IV antibiotics, reported its financial results for the first quarter ended March 31, 2025. The company noted a GAAP net loss but did not provide a specific figure. Iterum also disclosed non-GAAP financial measures, excluding certain expenses such as intangible asset amortization, share-based compensation, and adjustments related to financial instruments, which were detailed in the reconciliation tables provided. The company is preparing for the potential launch of ORLYNVAHTM, an antibiotic for uncomplicated urinary tract infections, by the fourth quarter of 2025. Additionally, Iterum has extended its cash runway into 2026, indicating a strengthened financial position to support its strategic objectives. The financial results focused on the company's operational goals, with no specific mention of variations in sales or revenue figures compared to previous periods.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iterum Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-069794), on May 13, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。